Biocon has initiated efforts to find a partner in China to conduct clinical trials on generic versions of Novo Nordisk’s diabetes drug ozempic and weight loss treatment wegovy. The company aims to eventually introduce these generic injectible drugs globally.
Biocon plans to collaborate with a Chinese partner to conduct trials involving over 500 patients. As reported by Reuters, Biocon’s generics would enter a competitive landscape, with over fifteen other generics or biosimilars currently being developed by Chinese drugmakers ahead of the patent expiry for semaglutide, a key component in ozempic and wegovy, expected in early 2026 in China.
